What is ivWatch?
Founded in 2010 and headquartered in Newport News, Virginia, ivWatch specializes in the development of advanced medical biosensor technology. The company is primarily focused on enhancing patient safety by mitigating the risks associated with intravenous therapy, such as infiltration and extravasation. By leveraging sophisticated sensor arrays and data analytics, ivWatch provides clinicians with real-time monitoring capabilities that significantly improve the efficacy of infusion treatments. Their market position is defined by a commitment to clinical excellence and the integration of hardware-software solutions that address high-stakes challenges in hospital settings.
How much funding has ivWatch raised?
ivWatch has raised a total of $36.9M across 8 funding rounds:
Private Equity
$2.7M
Private Equity
$2.8M
Private Equity
$668K
Private Equity
$12.8M
Private Equity
$14.8M
Private Equity
$2M
Debt
$350K
Debt
$778K
Private Equity (2011): $2.7M, investors not publicly disclosed
Private Equity (2012): $2.8M, investors not publicly disclosed
Private Equity (2014): $668K, investors not publicly disclosed
Private Equity (2015): $12.8M, investors not publicly disclosed
Private Equity (2017): $14.8M, investors not publicly disclosed
Private Equity (2017): $2M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Debt (2021): $778K supported by PPP
Key Investors in ivWatch
PPP
Public-Private Partnership
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for ivWatch?
Looking ahead, the strategic deployment of the $778K capital injection is expected to accelerate the commercialization of ivWatch's next-generation biosensor platforms. As the healthcare industry increasingly prioritizes patient-centric monitoring and the reduction of hospital-acquired complications, ivWatch is well-positioned to capture additional market share. Future growth initiatives will likely focus on expanding clinical adoption, deepening research and development efforts, and potentially exploring strategic partnerships to integrate their technology into broader hospital information systems. The company remains a key player to watch as it continues to refine its technological edge in the critical care monitoring space.
See full ivWatch company page
